Biohaven Pharmaceutical (BHVN) Given a $65.00 Price Target at Piper Jaffray Companies

Piper Jaffray Companies set a $65.00 price objective on Biohaven Pharmaceutical (NYSE:BHVN) in a research note released on Wednesday morning. The brokerage currently has a buy rating on the stock.

Other equities analysts have also recently issued research reports about the stock. Zacks Investment Research cut shares of Biohaven Pharmaceutical from a hold rating to a strong sell rating in a research report on Tuesday, July 17th. Needham & Company LLC reissued a buy rating and set a $48.00 price objective on shares of Biohaven Pharmaceutical in a research report on Friday, August 17th. Canaccord Genuity reissued a buy rating and set a $43.00 price objective on shares of Biohaven Pharmaceutical in a research report on Friday, August 17th. ValuEngine cut shares of Biohaven Pharmaceutical from a buy rating to a hold rating in a research report on Monday, August 20th. Finally, Cantor Fitzgerald began coverage on shares of Biohaven Pharmaceutical in a research report on Thursday, August 23rd. They set an overweight rating and a $55.00 price objective on the stock. One analyst has rated the stock with a sell rating, one has given a hold rating and nine have issued a buy rating to the company’s stock. Biohaven Pharmaceutical currently has a consensus rating of Buy and an average price target of $49.33.

Shares of BHVN opened at $34.92 on Wednesday. The firm has a market cap of $1.35 billion, a price-to-earnings ratio of -6.98 and a beta of 1.25. Biohaven Pharmaceutical has a 12 month low of $16.50 and a 12 month high of $44.28.



Biohaven Pharmaceutical (NYSE:BHVN) last issued its quarterly earnings results on Wednesday, November 14th. The company reported ($1.53) EPS for the quarter, missing the Zacks’ consensus estimate of ($1.05) by ($0.48). On average, equities research analysts expect that Biohaven Pharmaceutical will post -5.6 EPS for the current fiscal year.

Hedge funds and other institutional investors have recently made changes to their positions in the stock. SG Americas Securities LLC bought a new position in Biohaven Pharmaceutical in the 2nd quarter valued at about $191,000. Tower Research Capital LLC TRC lifted its position in Biohaven Pharmaceutical by 602.4% in the 3rd quarter. Tower Research Capital LLC TRC now owns 5,057 shares of the company’s stock valued at $190,000 after acquiring an additional 4,337 shares in the last quarter. Quantitative Systematic Strategies LLC bought a new position in Biohaven Pharmaceutical in the 2nd quarter valued at about $205,000. Shell Asset Management Co. bought a new position in Biohaven Pharmaceutical in the 3rd quarter valued at about $205,000. Finally, Legal & General Group Plc lifted its position in Biohaven Pharmaceutical by 111.3% in the 1st quarter. Legal & General Group Plc now owns 5,626 shares of the company’s stock valued at $145,000 after acquiring an additional 2,963 shares in the last quarter. 81.49% of the stock is currently owned by institutional investors and hedge funds.

About Biohaven Pharmaceutical

Biohaven Pharmaceutical Holding Company Ltd., a clinical-stage biopharmaceutical company, develops product candidates to treat neurological diseases, including rare disorders. Its lead product candidate is rimegepant, which is in Phase III clinical trials for the acute treatment of migraine. The company also develops trigriluzole, which is in a Phase II/III clinical trial used for the treatment of ataxias with an initial focus on spinocerebellar ataxia; and Phase II/III clinical trial for the treatment of obsessive compulsive disorders, as well as for the treatment of Alzheimer's diseases.

Recommended Story: Are all No-Load Funds Equal?

Analyst Recommendations for Biohaven Pharmaceutical (NYSE:BHVN)

Receive News & Ratings for Biohaven Pharmaceutical Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Biohaven Pharmaceutical and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply